b43-genistein immunoconjugate
mAbexperimentalADC
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2000 (NCT00004858)
Timeline
2000s
- Jan 1, 2000
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- B-lymphocyte antigen CD19INHIBITOR
CD19 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
- Payload
- genistein
Oral
No
Parenteral
No
Topical
No
Also known as
- b43-genistein immunoconjugate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00004858 | Phase 1 | Mar 1, 2000 | Parker Hughes Cancer Center |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Parker Hughes Cancer Center | Academic/Hospital | 1 | 1 | 1 | 2000 |
1 organizations
Page 1 / 1